MedTrace Logo

Bioequivalence of Two Lispro Formulations

NCT01133392 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2014-12-30

Study results available
· View outcomes & findings →

Summary

This study will compare how the body treats 2 different forms of insulin lispro and how they affect blood sugar levels.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Insulin lispro A

20 units (U) subcutaneously (SC).

DRUG

Insulin lispro B

20 U subcutaneously (SC).

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01133392 on ClinicalTrials.gov